Literature DB >> 11248804

C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge.

T M Ross1, Y Xu, R A Bright, H L Robinson.   

Abstract

The ability of the C3d component of complement to enhance antibody responses and protective immunity to influenza virus challenges was evaluated using a DNA vaccine encoding a C3d fusion of the hemagglutinin (HA) from influenza virus. Plasmids were generated that encoded a transmembrane HA (tmHA), a secreted form of HA (sHA), or a sHA fused to three tandem copies of the murine homologue of the C3d (sHA-3C3d). Analysis of the titers, avidity maturation, and hemagglutinin-inhibition activity of raised antibody revealed that immunizations with sHA-3C3d DNA accelerated both the avidity maturation of antibody to HA and the appearance of hemagglutinin-inhibition activity. These accelerated antibody responses correlated to a more rapid appearance of protective immunity. They also correlated to complete protection from live virus challenge by a single vaccination at a dose ten times lower than the protective dose for non-C3d forms of HA.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11248804      PMCID: PMC1635154          DOI: 10.1038/77802

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  25 in total

1.  DNA vaccines--designer vaccines for the 21st century.

Authors:  R A Seder; S Gurunathan
Journal:  N Engl J Med       Date:  1999-07-22       Impact factor: 91.245

Review 2.  Replication of orthomyxoviruses.

Authors:  A Portela; T Zürcher; A Nieto; J Ortín
Journal:  Adv Virus Res       Date:  1999       Impact factor: 9.937

Review 3.  DNA vaccines for viral infections: basic studies and applications.

Authors:  H L Robinson; T M Pertmer
Journal:  Adv Virus Res       Date:  2000       Impact factor: 9.937

4.  Studies on antibody responses following neonatal immunization with influenza hemagglutinin DNA or protein.

Authors:  T M Pertmer; H L Robinson
Journal:  Virology       Date:  1999-05-10       Impact factor: 3.616

Review 5.  The complement system and adaptive immunity.

Authors:  D T Fearon
Journal:  Semin Immunol       Date:  1998-10       Impact factor: 11.130

Review 6.  DNA vaccines.

Authors:  J J Donnelly; J B Ulmer; M A Liu
Journal:  Dev Biol Stand       Date:  1998

7.  Influenza vaccines: present and future.

Authors:  K Subbarao
Journal:  Adv Virus Res       Date:  1999       Impact factor: 9.937

8.  DNA immunization: effect of secretion of DNA-expressed hemagglutinins on antibody responses.

Authors:  C A Torres; K Yang; F Mustafa; H L Robinson
Journal:  Vaccine       Date:  1999-12-10       Impact factor: 3.641

9.  Construction of influenza haemagglutinin genes that code for intracellular and secreted forms of the protein.

Authors:  M J Gething; J Sambrook
Journal:  Nature       Date:  1982-12-16       Impact factor: 49.962

10.  Dose-response relationship after immunization of volunteers with a new, surface-antigen-adsorbed influenza virus vaccine.

Authors:  C W Potter; R Jennings; J P Phair; A Clarke; C H Stuart-Harris
Journal:  J Infect Dis       Date:  1977-03       Impact factor: 5.226

View more
  70 in total

1.  Enhanced avidity maturation of antibody to human immunodeficiency virus envelope: DNA vaccination with gp120-C3d fusion proteins.

Authors:  T M Ross; Y Xu; T D Green; D C Montefiori; H L Robinson
Journal:  AIDS Res Hum Retroviruses       Date:  2001-06-10       Impact factor: 2.205

2.  Enhancement of gp120-specific immune responses by genetic vaccination with the human immunodeficiency virus type 1 envelope gene fused to the gene coding for soluble CTLA4.

Authors:  Bishnu P Nayak; Gangadhara Sailaja; Abdul M Jabbar
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

3.  Regulation of DNA-raised immune responses by cotransfected interferon regulatory factors.

Authors:  Shin Sasaki; Rama Rao Amara; Wen-Shuz Yeow; Paula M Pitha; Harriet L Robinson
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

Review 4.  Evolution of complement as an effector system in innate and adaptive immunity.

Authors:  J Oriol Sunyer; Hani Boshra; Gema Lorenzo; David Parra; Bruce Freedman; Nina Bosch
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

Review 5.  Nonviral DNA vectors for immunization and therapy: design and methods for their obtention.

Authors:  Ernesto G Rodríguez
Journal:  J Mol Med (Berl)       Date:  2004-06-03       Impact factor: 4.599

6.  Contribution of C3d-P28 repeats to enhancement of immune responses against HBV-preS2/S induced by gene immunization.

Authors:  Li-Xin Wang; Wei Xu; Qing-Dong Guan; Yi-Wei Chu; Ying Wang; Si-Dong Xiong
Journal:  World J Gastroenterol       Date:  2004-07-15       Impact factor: 5.742

7.  Low concentrations of anti-Aβ antibodies generated in Tg2576 mice by DNA epitope vaccine fused with 3C3d molecular adjuvant do not affect AD pathology.

Authors:  Nina Movsesyan; Hayk Davtyan; Mikayel Mkrtichyan; Irina Petrushina; Tigran Tiraturyan; Ted Ross; Michael G Agadjanyan; Anahit Ghochikyan; David H Cribbs
Journal:  Hum Gene Ther       Date:  2010-11       Impact factor: 5.695

Review 8.  Complement-dependent transport of antigen into B cell follicles.

Authors:  Santiago F Gonzalez; Veronika Lukacs-Kornek; Michael P Kuligowski; Lisa A Pitcher; Søren E Degn; Shannon J Turley; Michael C Carroll
Journal:  J Immunol       Date:  2010-09-01       Impact factor: 5.422

Review 9.  Protective B cell responses to flu--no fluke!

Authors:  Elizabeth E Waffarn; Nicole Baumgarth
Journal:  J Immunol       Date:  2011-04-01       Impact factor: 5.422

10.  Immunization with a vaccine that combines the expression of MUC1 and B7 co-stimulatory molecules prolongs the survival of mice and delays the appearance of mouse mammary tumors.

Authors:  Vitaly Vasilevko; Anahit Ghochikyan; Nadya Sadzikava; Irina Petrushina; Mike Tran; Edward P Cohen; Patrick J Kesslak; David H Cribbs; Garth L Nicolson; Michael G Agadjanyan
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.